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1. Introduction 
A retinoblastoma is a neuroblastoma. It is a rare eye tumor of childhood that arises in the 
retina and represents the most common intraocular malignancy of infancy and childhood -1. 
It may occur at any age-2, but most often it occurs in younger children, usually before the 
age of two years. Most affected children are diagnosed before the age of five years-1,3. 
Intraocular tumours may exhibit a variety of growth patterns and is commonly seen in 
advanced countries. Extraocular retinoblastoma is common in developing countries because 
of delay in diagnosis.-4,5. 
In 60% of cases, the disease is unilateral (non hereditary) and the median age at diagnosis is 
two years. Retinoblastoma is bilateral (hereditary) in about 40% of cases with a median age 
at diagnosis of one year-1. Trilateral retinoblastoma is rare and refers to bilateral or 
unilateral retinoblastoma associated with an intracranial primitive neuroectodermal tumor 
in the pineal or suprasellar region-6. The median time interval from diagnosis of 
retinoblastoma to the development of a pineal region tumor was 24 months whereas the 
median time interval for the development of a suprasellar region tumor was 1 month-6. 
Untreated, retinoblastoma is fatal. In the developing countries, retinoblastoma presents with 
advanced disease with resultant 5 year survival of less than 50%-7 whereas patients present 
with intraocular disease in the developed countries due to availability of resources for early 
detection and treatment. The survival rate in these nations has improved from 
approximately 30% in the 1930s to over 90% in the 1990s -8,9. In the middle income 
countries, the survival rate is about 70% -10. Retinoblastoma occurs equally in males and 
females and there is no predilection for any race or any particular eye-11.  
2. What are the common symptoms of retinoblastoma 
a. Leucocoria (white papillary reflex or cat’s eye) is the most common accounting for 
about 60%- 80% of cases.-1,4,5. This is the most common type of presentation where 
there is high level of awareness such as in high income countries 
b. Strabismus occurs in about 20% of cases-1,4  
c. Orbital inflammation is seen in cases of tumour necrosis-4 
d. Proptosis follows orbital invasion. Secondary microbial infections are often present. 
This is a common type of presentation in most developing nations-12 due mainly to 
socioeconomic and cultural limitations resulting in delayed presentation -10 
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Fig. 1. Left leucocoria in a child with retinoblastoma. Courtesy. Wikipedia 
 
Fig. 2. Crossed eye in a child with retinoblastoma. Courtesy. Wikipedia 
 
Fig. 3. Courtesy. www.arquivosdamorte.com 
 
Fig. 4. Courtesy. projectmedishare.wordpress 
Advanced extra ocular retinoblastoma in African and South American children above 
e. Metastatic spread involves the brain/central nervous system, bones (especially skull 
bones and long bones), liver, spleen, Lymph nodes etc. This is worse in undeveloped 
economies due to late presentation and paucity of means of diagnosis -(-1,4,5,12) 
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f. Decrease in visual acuity-12 
  
Fig. 5. Courtesy. inctr.ctisinc.com. 
 
Fig. 6. Courtesy. www.jornallivre.com.br 
3. What are the common signs of retinoblastoma 
The clinical signs-5,12 vary with the stage of the tumour at the time of presentation. 
a. Early intraretinal tumour is a flat lesion which appears transparent or translucent. This 
type is commonly seen in high income countries where increase in awareness and early 
presentation are the norms 
b. Endophytic tumour projects from retinal surface toward the vitreous as a friable mass, 
frequently associated with fine blood vessels on its surface-4. The tumour resembles 
cottage cheese if calcified. Vitreous seeding may be present 
 
Fig. 7. Endophytic tumour. Courtesy. www.retinoblastomainfo.com  
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c. Exophytic tumour. This grows from the retina outward into the subretinal space with 
progressive retinal detachment. It may become a multilobulated mass with overlying 
retinal detachment. As the orbital structures are invaded, proptosis increases. 
Sometimes the grossly detached retina may be visible just behind the clear lens. 
Presence of vitreous hemorrhage may make the fundus hazy. Clinically, they may 
resemble coats disease 
 
Fig. 8. Fundus pictures of Retinoblastoma. Courtesy. journals.cambridge.org 
 
Fig. 9. Large exophytic retinoblastoma with calcification producing exudative retinal 
detachment. Courtesy. Wikimedia commons 
d. Occasionally, a retinoblastoma can assume a diffuse infiltrating feature characterized by 
a relatively flat infiltration of the retina by tumour cells without an obvious mass. In 
such cases, diagnosis may be more difficult and this pattern can simulate uveitis or 
endophthalmitis 
4. Less frequent signs of clinical presentations 
a. Secondary glaucoma with or without buphthalmos-4,13. This is rare. Pain may be a 
feature 
b. Anterior segment invasion-4, 13. Multifocal iris invasion may be associated with 
hyphema and iris neovascularization; painful red eye with pseudohypopyon due to 
tumour seeding into the anterior chamber. This is mostly unilateral involvement with 
no family history.-4 
c. Associated conditions. 13q deletion syndrome has retinoblastoma, dysmorphic features, 
mental retardation which may be associated in some patients-1 
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5. Differential diagnosis of retinoblastoma 
Some patients diagnosed initially with possible retinoblastoma prove, on referral to ocular 
oncologists and radiologists, to have pseudoretinoblastoma-4,5,13 and not retinoblastoma 
The more frequently encountered being 
Persistent hyperplastic primary vitreous  
Coats disease 
Ocular toxocariasis 
Others include: 
Preseptal or orbital cellulitis in extraocular spread 
Cataract 
Retinopathy of prematurity 
Uveitis 
Myelinated nerve fibre, optic nerve glioma, medulloepithelioma 
Organizing vitreous hemorrhage 
High myopia 
High anisometropia 
Retinal detachment 
6. Classifications of retinoblastoma (Rb) 
Several classifications of retinoblastoma have been developed to assist in prediction of globe 
salvage with preservation of useful vision where possible. There are two classifications for 
intraocular retinoblastoma currently in use. 
1. Reese-Ellsworth classification. Originally used to predict visual prognosis of affected 
eyes and globe salvage after external beam radiotherapy. It is still useful to compare 
newer treatment modalities with older ones-5 
Reese-Ellsworth classification of Retinoblastoma 
Group i. Favorable 
a. Solitary tumour less than 4 disc diameter in size at or behind the equator 
b. Multiple tumours, all less than 4 disc diameters in size all at or behind the equator. 
Group ii. Favorable 
a. Solitary tumour, 4 to 10 disc diameters in size at or behind the equator 
b. Multiple tumours , 4 to 10 disc diameters in size behind the equator 
Group iii. Doubtful 
a. Any lesion anterior to the equator 
b. Solitary tumours larger than 10 disc diameters behind the equator 
Group iv. Unfavorable 
a. Multiple tumours, some larger than 10 disc diameters 
b. Any lesion extending to the anterior ora serrata 
Group v. Very Unfavorable 
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a. Massive seeding involving over half of retina 
b. Vitreous seeding 
2. ABC classification of retinoblstoma-5 
To predict the preservation of the eye using all modern therapeutic methods 
Group A. Small tumours <3mm (about 0.1 inch) confined to the retina 
Group B. Larger tumours confined to the retina 
Group C. Localized seeding of the vitreous or under the retina <6.00mm (0.2inch) from the 
original tumour 
Group D. Widespread vitreous or sub retinal seeding which may have total retinal 
detachment 
Group E. No visual potential, eye cannot recover  
Others 
3. Philadelphia Practical Grouping System of Retinoblastoma Based on Clinical Features.-
14 
To quantify retinoblastoma and its associated features without need to refer to complex 
qualification criteria. Proceeding from the lowest to the highest grouping is meant to 
imply worse ocular prognosis. This is a simpler and newer classification to Reese-
Ellsworth. 
 
Group Abbreviations Features success* 
1. T Tumour only# 100% 
2. T+SRF Tumour + subretinal fluid 91% 
3. T + FS  Tumour +focal seeds 
SRS ≤ 3mm from tumor 
VS ≤ 3mm from tumor 
59% 
4. T +DS Tumour +diffuse seeds 
SRS >3mm from tumor 
VS > 3mm from tumor 
12% 
5. High Risk Tumor plus(any one) 
a. Neovascular glaucoma 
b. Opaque media from hemorrhage 
c. Invasion of post laminar optic nerve, choroid 
(<2mm), sclera, orbit or anterior chamber. 
NA 
*success after treatment with systemic chemotherapy with or without local consolidation is defined as 
avoidance of enucleation or need for external beam radiotherapy. 
# Regardless of tumour number, size or location 
DS=Diffuse seeds, FS=Focal seeds, SRF=Sub retinal fluid, SRS=Sub retinal seeds, T= Tumour, 
VS=Vitreous seeds, NA= Not applicable because these patients had primary enucleation. 
4. International retinoblastoma classification 
It is useful in guiding the selection of the most appropriate treatment methods and 
predicting chemo reduction success.-15,16 
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Group Features
A Small tumour ≤3mm
Large tumour >3mm
B Macular ≤3mm to foveola
Juxtapappilary: ≤3mm to disc
Subretinal fluid: ≤3mm from the margin
Focal seeds
C Subretinal seeds ≤3mm
Vitreous seeds ≤3mm
Both subretinal or vitreous seeds ≤3mm
Diffuse seeds.
D Subretinal seeds > 3mm
Vitreous seeds: > 3mm
Both subretinal and vitreous seeds > 3mm
E Extensive retinoblastoma occupying more than 50% or
Neovascular glaucoma or opaque media from hemorrhage to anterior chamber, 
vitreous or subretinal space 
5. Classification encompassing entire spectrum of retinoblastoma disease stages-17.  
This is an internationally proposed work to adopt a uniform staging system in which 
patients are classified according to the extent of the disease and the presence of overt extra 
ocular extension. 
Stage 0. Confined to the retina. Eye treated conservatively. 
Stage 1. Confined to the retina. Eye enucleated, resected histologically. 
Stage 2. Confined to the globe. Eye enucleated, microscopic residual tumour. 
Stage 3. Regional extra ocular spread. a. Overt orbital disease. b. preauricular or cervical 
lymph node extension 
Stage 4. Distant metastasis. 1. Hematogenous metastasis: a. Single lesion. b. Multiple lesions. 
2. Central nervous system (CNS) extension: a. prechiasmatic lesion. b. CNS mass. c. 
Leptomeningeal disease.  
6. Extra-ocular retinoblastoma have 4 major types-4,5.  
a. Optic nerve involvement 
b. Orbital invasion 
c. CNS involvement 
d. Distance metastasis. 
These are rare in developed countries such as the United States of America but 
unfortunately are still common in the developing nations due to delayed presentation and 
lack of access to proper health facility-4.  
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7. Racial differences in the time of presentations of retinoblastoma patients 
An African series recorded a substantial delay before first presentation compared to what 
obtained in Europe-11,18. Essentially, many that delayed in African setting would have 
sought alternative treatments from spiritualists, traditional healers or quacks. Financial 
difficulties in funding treatment also caused delays-18. The series found a mean lag time 
value of 10 months in the study while the study done in London and Argentina showed lag 
time of 8 weeks-19 and 6 months-20 respectively. It was concluded that prolonged lag time 
is associated with higher risk of extra-ocular spread-19, 20. Also, in the same study, disease 
staging at presentation was found to be more advanced in the African series and in India-21 
compared to what obtains in Europe and America. In Argentina, over 60% of the cases 
recorded had intraocular disease-20 when compared with African series-7 where majority 
presented with large extraocular, sometimes fungating disease(Figures 3 ). In developing 
countries, retinoblastoma is unfortunately accompanied by a high mortality rate due to a 
significantly delayed diagnosis made at advanced stages of the disease-18,21,22 
8. Are there differences in presentation in children and adults? 
Anterior segment invasion by diffuse retinoblastoma is seen in older children with average 
age of 6 years as compared to 18 months in typical cases-4,5. This is unilateral and 
nonhereditary. Retinoblastoma in adults is very rare. Age at presentation was from 20 years 
and above among the 23 recorded cases in literature.-3 Clinical presentations were 
essentially different compared to those in children- 3. 
9. Laterality 
Bilaterally affected children would carry one germinal mutation from conception and 
thereafter acquire the second mutation necessary for the expression of Rb. Unilaterally 
affected children would have to acquire two somatic mutations and this would explain why 
they would present at a later age than bilateral patients. The bilateral retinoblastoma patient 
present earlier in time than does unilateral retinoblastoma patients -23. Within early or 
advanced intraocular disease categories, the unilateral retinoblastoma patient will present 
later than does the bilateral. A series found that bilaterally affected children were diagnosed 
at an average age of 13months compared to the average of 24months for unilateral Rb 
patients-23. This average age for diagnosis of unilateral retinoblastoma is higher in 
developing nations-18,21 because of late presentation.  
Trilateral retinoblastoma patients manifest either as unilateral or bilateral diseases and are 
characterized by early onset and predisposition to developing secondary non-ocular, 
intracranial malignancies -24, 25. Most cases of trilateral retinoblastoma, which occur in 
about 8% of heritable retinoblastoma-25 are found in the midline pineal region, but they can 
also occur in the suprasellar and parasellar regions. These tumors usually occur several 
years after successful management of ocular retinoblastomas without evidence of direct 
extension or distant metastasis. -26. The nonocular tumors frequently present include 
intracranial primitive neuroectodermal tumors and sarcomas -27.  
It is possible that many cases of pineoblastoma were previously misinterpreted as metastatic 
retinoblastoma to the brain. Unlike other second tumors, the pineoblastoma usually occurs 
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during the first 5 years of life-25 whereas second tumors often take many decades to 
develop, the incidence increasing with time, with a median age of17years (10- 32years)-28. 
The mean interval from the time of diagnosis of retinoblastoma to discovery of the 
intracranial tumor was 21.5 months-29. Unfortunately, pineoblastoma is usually fatal. 
Hence, patients with bilateral or familial retinoblastoma are advised to have screening for 
pineoblastoma using computed tomography or magnetic resonance imaging of the brain 
twice yearly for the first 5 years of life. In some cases the intracranial tumor preceded the 
diagnosis of retinoblastoma.-25,30. 
Unilateral intraocular retinoblastoma associated with intracranial tumor was more likely to 
occur in patients with suprasellar region tumors than pineal region tumors (P < 0.015). The 
median survival after the diagnosis of an intracranial tumor was 6 months regardless of the 
location of the intracranial tumor. For patients who received no treatment for the 
intracranial tumor the median survival was 1 month whereas it was 8 months for those who 
received treatment. Children who were asymptomatic at the time of diagnosis of the 
intracranial tumor had a better overall survival than those who were symptomatic (P = 
0.002).-6. Tumors of the suprasellar region present earlier than tumors of the pineal region 
after the diagnosis of intraocular tumors. The intracranial tumour represents ectopic foci of 
retinoblastoma rather than metastatic spread-31 
 
Fig. 10. Aspect of trilateral retinoblastoma on MRI. Courtesy. Wikimedia commons 
10. A short mechanistic explanation for the clinical manifestations 
Leucocoria is caused by massive replacement of vitreous by tumor and altered red pupillary 
reflex.  
Strabismus is due to loss of central vision following retinal detachment, vitreous 
hemorrhage, glaucoma or optic nerve involvement singly or in combination. 
Proptosis is as a result of tumour growth with displacement of normal tissues or seeding 
into the tissues and consequent enlargement of the tissues. 
Orbital inflammation follows release of toxins from tissue necrosis. 
Mucopurulent or fungating ocular mass results from mixed microbial infections due to 
neglect or mismanagement. 
Convulsions and neurological deficits arise from spinal cord or brain metastasis. 
Palor is due to anemia following bone marrow metastasis, oncogenic drug administration 
and radiotherapy 
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Easy brusability/ bleeding diasthesis are due to low platelet count following bone marrow 
involvement, oncogenic drug use or radiotherapy 
Bone masses following metastasis may produce aches and discomfort 
Headache results from raised intracranial pressure. 
Blindness results from optic nerve involvement, retinal detachment, vitreous hemorrhage  
11. Clinical diagnosis of retinoblastoma 
Diagnosis is made from history, physical, histological and radiological examinations; blood 
chemistry, cerebrospinal fluid and marrow aspiration analysis. 
1. Intraocular tumours 
a. Well dilated fundoscopy is mandatory to visualize tumours and classify the 
condition. It is done under general anesthesia 
b. Indirect ophthalmoscopy with scleral indentation after full dilatation of both eyes is 
a must. Tumours anterior to the equator are visualized 22. This method determines: 
 The unilateral or bilateral nature of the lesions 
 The number of tumors 
 Their position in the retina (posterior pole and anterior retina) 
 The tumor size (diameter and thickness) 
 The subretinal fluid and tumor seeds 
 The vitreous seeding: localized or diffuse 
 The anatomical relations with the optic disc and macula. 
All these parameters should be taken into account for grouping the retinoblastoma and for 
making therapeutic decisions - 22. 
c. Ocular ultrasound detects size, location and extent of tumour22 
 
Fig. 11. Ocular ultrasound of large exophytic retinoblastoma. Courtesy. www.retinaatlas.com  
d. Cranial/ orbital computed tomography (CT) scan can detect intraocular 
calcifications and extent of the tumour-22. 
e. Magnetic resonance imaging (MRI) of the brain and orbits is the most sensitive 
means of evaluating for extraocular extension. It gives better delineation of the 
optic nerve and also the pineal area-22,32 
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f. Ultrasound biomicroscopy: provides adequate resolution of retinoblastoma 
anterior to the ora serrata in the ciliary region. Failure to detect anterior tumors 
early can compromise the chances of saving the eye and increase the risk of 
extraocular disease-33 
2. Extraocular tumours 
a. Optic nerve involvement- MRI and histology 
 
Fig. 12. MRI pattern of retinoblastoma with optic nerve involvement (sagittal enhanced T1-
weighted sequence). Courtesy. Wikipedia  
b. Orbital invasion causing proptosis/lid swelling - orbital ultrasound and CT scan.  
c. Central nervous system (CNS) involvement causing brain and spinal cord lesions- 
MRI, CT scan and intracranial pressure.  
d. Metastatic disease-. Abdominal ultrasound detects pathology of the involved 
abdominal organs. During physical examination, Liver, spleen and bone masses 
and enlargements could be palpated. 
Skeletal survey 
Bone marrow assay 
Blood chemistry  
Cerebrospinal fluid analysis and cytology 
e. Non ocular tumours: MRI is the choice in detecting pinealoblastomas especially if a 
contrast material is added 22. 
12. Metastatic retinoblastoma 
Significant differences were found in the occurrence of metastasis: in Low income countries 
(LICs), 32% (range, 12-45%); in lower Middle income countries (MICs), 12% (range, 3-31%) 
and in upper MICs, 9.5% (range, 3-24%; p = 0.04).-34 
An average of 12 months elapsed between initial diagnosis of eye disease and the first signs 
and symptoms of metastasis-35 Those at greatest risk for metastasis show features of 
retinoblastoma invasion beyond the lamina cribrosa in the optic nerve, in the choroid (>2 
mm dimension), sclera, orbit, or anterior chamber-35. Optic nerve invasion was the 
commonest extraocular site of spread-18. Advanced extraocular retinoblastoma correlates 
with longer lag times from the onset of symptoms to the diagnosis-20. A study showed that 
at presentation, the mean patient age was 45 months (range, 13-86 months) and all patients 
with metastatic retinoblastoma had histopathologic or MRI evidence of unilateral 
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extraocular disease characterized by optic nerve involvement, extrascleral extension, or 
both.-36  
When retinoblastoma extends outside the eye, it is difficult to cure, even with sophisticated 
and intense treatments-35,37. The prognosis for survival is very poor in developing nations 
where these treatment modalities are scarce. 
Of the 71 orbital recurrence cases followed up over a period of 3–208 months (mean 34.8 
months) in a study, 60 patients developed metastatic disease (85%), and 53 of the 71 patients 
died from metastatic retinoblastoma (75%).-38. In developing countries, the diagnosis of 
retinoblastoma is frequently made at later stages of the disease when extraocular 
dissemination has already occurred; therefore, ocular and patient survival rates are lower in 
these countries than in developed countries-34. Metastatic spread is uncommon in 
developed countries because of early detection and proper therapy-8. 
Presenting symptoms of metastasis -38,39 
Eye: eye lid swelling, visible mass in the orbit, ill fitting prosthesis, Ocular deviation, 
bleeding socket. 
Constitutional signs: lethargy, somnolence, fever, irritability, headache, anorexia, vomiting. 
Bone: Pains in the back or limbs 
Presenting signs of metastasis-38 ,39 
Focal neurologic deficit/seizure/nystagmus 
Mass on the bone, body, eye or orbit (proptosis) 
Pallor, Easy bruisability eyelid ecchymosis, eyelid swelling involving contra lateral eye. 
Nose bleed 
Hepatosplenomegaly 
 
 
 
 
Fig. 13. Metastatic retinoblastoma in an African child. Courtesy. righthealth.com 
www.intechopen.com
 
Review of Clinical Presentations of Retinoblastoma 
 
15 
 
 
 
 
 
Fig. 14. Retinoblastoma with extension into choroid. Courtesy. www.thirdeyehealth.com 
13. Useful tests to determine the extent of metastatic disease
[40]
 
MRI of brain and orbit 
Computed tomography scan of the brain and spine cord 
Lumber puncture for CSF analysis 
Electoencephalogram 
Bone marrow aspiration 
Bone scans 
Automated blood chemistry analysis 
Histopathology of enucleated/ exenterated eye, orbital biopsy, optic nerve and extrascleral 
extension. 
14. Are some patients at particular risk? 
1. Children with the heritable form of retinoblastoma are at high risk for developing 
subsequent malignancies, most commonly sarcomas. This risk is greater for those 
children with the heritable form of the disease who were exposed to ionizing 
radiation at age <1 year-41. The most frequent non ocular tumors encountered are 
osteogenic sarcomas of the skull and long bones, soft tissue sarcomas, cutaneous 
melanomas, brain tumors, and lung and breast cancer. Patients who survive a second 
tumor are at risk for a third, fourth and even fifth non ocular tumor-42. Subsequent 
malignant neoplasms are a major cause of premature death in survivors of hereditary 
retinoblastoma-43 
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2. Patients presenting with high-risk pathology features, such as microscopic tumor 
invasion of the postlaminar optic nerve (i.e. beyond the lamina cribrosa), choroid, or 
sclera, are at higher risk of extraocular retinoblastoma relapse. However, the relapse 
rate is different among the different groups. Such cases are more frequent in developing 
countries, occurring in more than 50% of children in some middle income countries 
compared to developed countries-10 
3. Patients presenting with glaucoma and or buphthalmia have a significantly higher risk 
for the occurrence of pathology risk factors (PRF) including those resulting in 
microscopically residual disease. Major choroidal invasion and postlaminar optic nerve, 
scleral extension and possibly anterior segment invasion were considered PRFs-44,45 
15. Recurrence of retinoblastoma tumours 
a. Intraocular tumors may regrow after aggressive local and systemic therapy. Following 
chemoreduction and focal consolidation, tumor recurrence was found in 18% of tumors 
at 7 years and the most important factor predictive of recurrence was increasing tumor 
thickness-14. 
b. The diagnosis of orbital tumor recurrence was made between 1 and 24 months after 
enucleation in a study (mean 6 months), with 69 of the 71 patients (97%) being 
diagnosed within the first 12 months-38. 
c. Relapse. When analyzing patterns of failure in the 19 eyes that relapsed following 
external beam radiotherapy, a total of 28 failure sites were identified and consisted of 
progression to vitreous seeds in 7(25% of failure sites), recurrences from previously 
existing tumours in 10cases (36% of failure sites) and development of new tumours in 
previously uninvolved retina in 11 instances (39% of failure sites)-40.  
 
 
 
 
 
Fig. 15. Recurrent right retinoblastoma after enucleation in a 2 year old child with advanced 
bilateral retinoblastoma. Courtesy. Jacky Adura 
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16. Regression of retinoblastoma tumours 
Retinoblastoma shows a variety of regression patterns. 
a. Spontaneous regression of retinoblastoma is possible and may be asymptomatic 
resulting in the development of a benign retinocytoma or it can be associated with 
inflammation and ultimately phthisis bulbi-5 
b. In evaluating retinoblastoma regression patterns following chemoreduction and 
adjuvant therapy, regression patterns included type 0 (no remnant), type 1 (calcified 
remnant), type 2 (noncalcified remnant), type 3 (partially calcified remnant), and type 4 
(flat atrophic scar). The retinoblastoma assumes a smaller size with stable margins and 
frequently, some degree of calcification-46. Some tumors become completely calcified 
whereas others have minimal or no calcification. Following chemoreduction, most small 
retinoblastomas (3mm or less) result in a flat scar, intermediate tumors (3- 8mm) in a 
flat or partially calcified remnant and large tumors (8mm or more) in a more completely 
calcified remnant-46.  
17. Retinoblastoma mortality – Prognosis 
Mortality from retinoblastoma is increased in metastasis-35, trilateral cases -25 and second 
malignant neoplasms-47, the last two are seen mostly in association with bilateral 
retinoblastoma-48 and in sporadic unilateral cases that are hereditary-49 
If left untreated, the mortality rate of retinoblastoma is about 99%. The major factor in 
mortality rates for patients with retinoblastoma is whether or not the tumor is confined to 
the eye. Extraocular spread increases mortality rates markedly. If there are tumor cells at the 
cut end of the optic nerve (with an enucleation), the mortality rate is much higher. Even if 
tumor is in the lamina cribrosa but the cut end of the optic nerve is free of tumor, mortality 
rates are elevated. However, when tumor is confined to the globe when enucleated, survival 
rates are greater than 92%-48  
In evaluating long-term visual outcome following chemoreduction, the clinical factors that 
predicted visual acuity of 20/40 or better were a tumor margin at least 3 mm from the 
foveola and optic disc and an absence of subretinal fluid-22,50. Retaining visual function 
depends on the tumor size and location-48. 
Over 95% of children with retinoblastoma in the United States and other medically 
developed nations survive their malignancy, whereas approximately 50% survive 
worldwide-22. This discrepancy is largely due to earlier detection in the United States and 
developed nations when the tumor is confined to the eye, whereas in underdeveloped 
regions, retinoblastoma is often detected after it has invaded the orbit or brain-51. The 
survival rate of patients with retinoblastoma is low in Nigerian, an underdeveloped 
nation, due to high mortality associated with late presentation and poor facility for 
detection and treatment-52 unlike in developed countries. Again, in some African or 
Asian countries, the survival rate is virtually zero, because most patients do not complete 
therapy or are lost to follow-up-53. The mean interval from diagnosis of the ocular tumor 
to death was 46 months and from diagnosis of the intracranial tumor to death was 17 
months-29 
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18. Late adverse effects of therapy for retinoblastoma
[54,55]
 
1. Patients who received external beam irradiation are at risk for the development of 
secondary tumors within and outside the field of treatment. Radiation optic neuropathy 
and retinopathy can occur. Patients can experience ocular surface abnormalities, severe 
dry eye and cataracts. Radiation can also affect growing orbital bones, producing facial 
hypoplasia and contracted socket. Pituitary dysfunction may occur. 
2. Chemotherapeutic agents are known to produce numerous potential side-effects. These 
include lowered immune status, increased incidence of secondary leukemia, infertility; 
auditory, cardiac, gonadal and renal dysfunction.  
3. Cryotherapy can cause retinal thinning and retinal holes. This can be followed by 
retinal detachment, vitreous hemorrhages, tumor seeding and cataract. 
4. Laser treatments can be associated with iris burns, vitreous hemorrhage, and tumor 
break with vitreous seeding. 
5. Intra arterial chemotherapy: Risks associated with general anaesthesia, bleeding from 
arterial puncture, hematoma or arterial thrombus; drop in vision or total loss of vision 
in the affected eye, 3rd nerve palsy and sometimes risk of cerebrovascular accident 
6. Psychological/Visual effects. The child may be blind from enucleation or from the 
disease itself. The child may present with low self esteem, limited social function and 
limited educational attainment.  
Another study showed that vitreoretinal complications occurred in 6.8% of patients 
undergoing therapy for retinoblastoma. These included retinal tears, rhegmatogenous 
and tractional retinal detachment, subretinal fibrosis, vitreous traction bands, preretinal 
fibrosis and pseudo-vitreous seeding. They were more often seen when systemic 
chemotherapy was combined with external beam radiation, cryotherapy and local 
chemotherapy-56. 
19. Complication of retinoblastoma 
Metastasis to the orbit, the optic nerve and then to the central nervous system. Other distant 
spread may involve the abdominal organs, bones and lymph nodes.  
Loss of eye in enucleation 
Blindness 
Cosmetic deformity from enucleation, prosthesis and potential orbital hypoplasia secondary 
to external beam radiation therapy. 
Second malignancy. This is mainly seen in patients with bilateral retinoblastoma who 
receive external beam radiation therapy-55. 
Life threatening especially in advanced cases. 
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